BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 33120845)

  • 1. Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
    Wang L; Yan X; He J
    Medicine (Baltimore); 2020 Oct; 99(43):e22923. PubMed ID: 33120845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review.
    Wang X; Wang J; Zhang L
    Medicine (Baltimore); 2019 May; 98(19):e15537. PubMed ID: 31083206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
    Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy.
    Peterson JF; He RR; Nayer H; Cuevo RS; Smadbeck JB; Vasmatzis G; Greipp PT; Ketterling RP; Hoppman NL; Baughn LB
    Cancer Genet; 2019 Sep; 237():51-54. PubMed ID: 31447065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
    Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM
    Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
    Burry LD; Seki JT
    Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
    Li Y; Yu J; Xu Q; Zhang K
    Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
    Liso V; Specchia G; Pogliani EM; Palumbo G; Mininni D; Rossi V; Teruzzi E; Mestice A; Coppi MR; Biondi A
    Cancer; 1998 Oct; 83(8):1522-8. PubMed ID: 9781945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review.
    Zhang G; Song Y; Wan L; Liu K; Qiu S; Wang J; Mi Y
    Blood Sci; 2022 Apr; 4(2):93-96. PubMed ID: 35957665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
    Koh LP; Goh YT; Teoh G; Tan P
    Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Henzan H; Takase K; Kamimura T; Mori Y; Yoshimoto G; Iwasaki H; Nagafuji K; Ogawa R; Eto T; Uchida N; Fujisaki T; Kato K; Minami M; Kikushige Y; Akashi K; Miyamoto T;
    Int J Hematol; 2020 Sep; 112(3):349-360. PubMed ID: 32524309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
    Dang CC; Guan YK; Lau NS; Chan SY
    J Oncol Pharm Pract; 2020 Dec; 26(8):2034-2037. PubMed ID: 32279594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.